A small fraction of individuals with HIV-1 infection develop antibodies that effectively neutralize the majority of existing HIV-1 isolates [1] [2] [3] [4] [5] [6] [7] . Single-cell antibody cloning methods revealed that this serum neutralizing activity is due to one or a combination of monoclonal antibodies that target different nonoverlapping epitopes on the HIV-1 envelope spike 1, 3, 5, 6 . These sites of vulnerability include the membrane proximal region [8] [9] [10] , the base of the V3 loop and surrounding glycans [11] [12] [13] [14] , the V1/V2 loops at the apex 15,16 , the CD4 binding site [17] [18] [19] and a series of epitopes that span gp120 and gp41 (refs. 20,21).
a r t i c l e s 1 8 6 VOLUME 23 | NUMBER 2 | FEBRUARY 2017 nature medicine of infected cells and increased breadth and potency of host anti-HIV-1 antibody responses 33, 37 . Finally, in participants who carried sensitive viruses, the administration of two or four 3BNC117 30mg/kg infusions significantly delayed viral rebound during interruption of antiretroviral therapy (ART) and resulted in viral suppression for 6.7 or 9.9 weeks, respectively 38 . However, both 3BNC117 and VRC01 recognize the same target on the HIV-1 envelope protein, and whether bNAbs that target additional epitopes on the HIV-1 spike are safe and clinically effective has not been determined.
RESULTS
10-1074 shows a favorable pharmacokinetic profile and is well tolerated 10-1074 is a highly potent anti-HIV-1 antibody isolated from an individual with an HIV-1 clade A infection 11 . It targets a carbohydratedependent epitope in the V3 loop of the HIV-1 envelope spike 11, 14 . When tested against large panels of HIV-1 pseudoviruses in TZM.bl neutralization assays in vitro, 10-1074 neutralizes 60.5% of 306 strains comprising 13 subtypes and 88.5% of 26 clade B strains, at an average 80% inhibitory concentration (IC 80 ) of 0.18 µg/ml and 0.13 µg/ml, respectively ( Supplementary Fig. 1a ,c) 39 . When tested against primary HIV-1 isolates from 179 individuals with HIV-1 infection (77 off and 102 on antiretroviral therapy, ART) living in the United States or in Germany, 77.7% of cultures were neutralized, with a mean IC 80 of 0.67 µg/ml ( Supplementary Fig. 1b,c) . Table 1 ). The antibody was generally safe and well tolerated by all participants. No grade 3, 4 or serious treatment-related adverse events or notable laboratory abnormalities were observed during a follow-up period of up to 168 d (total of 5,447 patient days; Supplementary Table 2) .
10-1074 serum levels were determined by TZM.bl neutralization assay, which measures the amount of active antibody in the serum (Supplementary Table 3 ) 34, [40] [41] [42] . Similar to 3BNC117 (refs. 34,35), 10-1074 was eliminated more rapidly in HIV-1-infected individuals than in participants without HIV-1 (Fig. 1b) Table 4 ). The differences in antibody half-life might be due to the presence of the target antigen in the individuals with HIV-1 infection and accelerated clearance of antigen-antibody immune complexes [34] [35] [36] 43 . Moreover, HIV-1 infection is associated with increased levels of immunoglobulins, which potentially results in reduced antibody half-lives 44 .
10-1074 reduces viremia in individuals infected with sensitive HIV-1 strains As expected, no changes in viral load (VL) were detected after infusion in three ART-suppressed individuals (VL < 20 copies/ml) ( Table  1, Supplementary Tables 1 and 3a) . At the time of enrollment, HIV-1 RNA levels in the 16 individuals with HIV-1 who were not on ART ranged from 840 to 77,610 copies/ml (geometric mean of 12,851 copies/ml; Table 1 and Supplementary Tables 1 and 3a) . The three individuals who received a dose of 10 mg/kg of the antibody showed a rapid decrease in viremia of 1.08-1.56 log 10 copies/ml, with a nadir at 7-9 d (Fig. 2a, Supplementary Fig. 3a and Supplementary  Table 3a ) and a return of viral RNA copy number to baseline levels within 3-4 weeks after infusion (Fig. 2a, Supplementary Fig. 3a and Supplementary Table 3a) . Out of 13 participants with viremia who received a dose of 30 mg/kg, 11 experienced a rapid decrease in their HIV-1 RNA levels. The two individuals who failed to respond, designated 1HD2 and 1HD9K, were infected with 10-1074-resistant HIV-1 variants before undergoing 10-1074 infusion (Fig. 2, Fig. 3b and Supplementary Fig. 4) Table 3 ). Scr, screening visit; pre, pre-infusion visit. who received 30 mg/kg of 10-1074 and harbored sensitive strains was 1.52 log 10 copies/ml (range, 0.9-2.06 log 10 copies/ml). The nadir was reached after an average of 10.3 d (range 7-25 d). When compared to pretreatment HIV-1 RNA levels (day 0), the decrease in viremia in this group was significant from about day 3 to day 27 post-infusion (Fig. 2a, Supplementary Table 3a and Supplementary Fig. 5 ). The average 10-1074 serum concentrations at viral rebound (defined as an increase of at least 0.5 log 10 copies/ml above nadir and confirmed in the follow-up visit) were 23.7 and 76.9 µg/ml in the 10 and 30 mg/kg dose groups, respectively (Fig. 2b) . The most sustained response, 58 d, occurred in individual 1HD6K, who exhibited a 10-1074 concentration of 6.5 µg/ml at rebound (Fig. 2b) . Maximum drop in viral load (∆log 10 copies/ml) was not correlated with the 10-1074 neutralization sensitivity (IC 80 ) of primary virus cultures obtained before infusion (Spearman's rho: −0.05) or with baseline viremia (Spearman's rho = −0.19) (Fig. 2c,d ). Relative T cell subsets remained unchanged (Supplementary Fig. 6 and Supplementary Table 3a) . We conclude that 10-1074 administration rapidly decreases viremia in individuals infected with sensitive HIV-1 strains.
Viremia at rebound contains a mixture of different escape variants
To examine the precise nature of the virologic effects of 10-1074 infusion, we performed single-genome sequencing (SGS) before and after infusion on circulating viruses from 15 out of 16 individuals with viremia. We retrieved a total of 1,111 full-length envelope sequences (Supplementary Table 5 ). Study subjects were infected with epidemiologically distinct clade B viruses ( Fig. 3a and Supplementary  Fig. 4 ). Consistently with different durations of HIV-1 infection, day 0 env diversity and phylogenetic complexity varied between participants ( Fig. 3a and Supplementary Fig. 4 ). The 10-1074 antibody makes crucial contacts with Env glycans at a potential N-linked glycosylation site (PNGS) at position N332 and with the 324 G(D/N)IR 327 motif at the base of the V3 loop 11, 14, 45 . With the exception of the two individuals who were resistant to 10-1074 (1HD2 and 1HD9K) and participant 1HC1, all day-0 plasma env sequences in the remaining ten individuals displayed a PNGS at position N332 and an intact 324 G(D/N)IR 327 motif, which suggests that the corresponding viruses are sensitive to 10-1074 (Fig. 3b,  Supplementary Fig. 4 and Supplementary Table 5 ). Individual 1HC1, who responded to 10-1074 infusion with a drop of only 1.0 log 10 copies/ml in viremia, carried an N332T mutation in 2 of 19 viruses sequenced before infusion ( Fig. 3b and Supplementary Fig. 4 ). The two individuals who did not respond carried single amino acid (AA) mutations at either the PNGS (N332T in 1HD2) or a 10-1074 contact residue in the protein-binding motif (D325E in 1HD9K) in 100% of day-0 plasma env sequences ( Fig. 3b and Supplementary  Fig. 4) .
Four weeks after infusion, 370 intact envelope sequences were obtained from 13 individuals who responded to 10-1074. Over 91% of sequences showed recurrent AA mutations, most of which (97%) eliminated the PNGS at position 332 by mutating either N332 or S334 (Fig. 3c,d) . 3% of mutated sequences showed changes at D/N325 in the 324 G(D/N)IR 327 motif (Fig. 3c,d and Supplementary Table 5 ). Viral sequences comprised a mixture of different variants, all of which were closely related to pre-infusion day-0 viruses, which highlights the multiclonal origin of rebound viremia ( Fig. 3a and Supplementary  Fig. 4 ). Mutations at AA positions 325, 332 and 334 were mutually exclusive with mutations at only one of three positions in any given virus ( Supplementary Fig. 4) . Two of the most frequent mutations, S334N and N332S, were found in 12/13 (S334N) and 11/13 (N332S) of the individuals analyzed (Fig. 3c,d and Supplementary Fig. 4) .
On the nucleotide level, 99% (319 out of 322) of mutations affecting the PNGS at N332 were due to a single change relative to day 0 (Supplementary Fig. 7) . The majority of these mutations were transitions, consistent with reverse transcriptase (RT) errors 46 . Day-0 viruses from 10 out of 13 individuals who responded to 10-1074 infusion carried the triplets AAC-ATT-AGT at positions 332-334 in 99% of their pre-infusion sequences (Supplementary Fig. 7) . Notably, these individuals exhibited a very similar spectrum of AA escape mutations at week 4 ( Fig. 3d and Supplementary Fig. 7 ). By contrast, individual 1HD6K, who maintained viral suppression for over 8 weeks, exhibited a different set of codons, i.e., AAT-ATT-TCT, in the antibody target region. This probably resulted in a different spectrum of escape mutations, which indicates that the codon composition in this region might influence viral escape from 10-1074 ( Fig. 3d  and Supplementary Fig. 7) .
To determine whether loss of the PNGS at position N332 or 324 G(D/N)IR 327 mutation is associated with resistance to 10-1074, we performed neutralization assays on 114 pseudoviruses expressing envelope proteins derived from circulating viruses on day 0 (55 pseudoviruses) and 4 weeks (59 pseudoviruses) after 10-1074 infusion (Fig. 3e, Supplementary Fig. 4 and Supplementary Table 6 ). The pseudoviruses were tested against antibodies currently in, or being considered for, clinical testing. These include 3BNC117 and VRC01, which target the CD4 binding site [34] [35] [36] 38 ; 10-1074 and PGT121, which recognize the base of the V3 loop and surrounding glycans 11, 12 ; and PGDM1400, which recognizes a conformational epitope at the top of the envelope spike 16 . PGT121 differs from 10-1074 in that it interacts more strongly with glycans at positions N137, N156 and N301, and as a result, PGT121 is thought to be less dependent on the glycan at N332 than 10-1074 (refs. 13,14) . As expected, there was no correlation between the emergence of resistance to 10-1074 and resistance to antibodies targeting nonoverlapping sites on the HIV-1 Env protein (3BNC117, VRC01 or PGDM1400; Fig. 3e) . Consistent with data obtained by examining large panels of HIV-1 pseudoviruses, there was no significant difference in sensitivity against 10-1074 and PGT121 (mean GEO IC 80 = 0.10 versus 0.08 µg/ml; P = 0.19; Fig. 3e ) and 3BNC117 was generally more potent than VRC01 (mean GEO IC 80 = 0.37 versus 1.18 µg/ml; P = 5.1 × 10 −6 ; Fig. 3e ). In 10 of 11 individuals from whom envelopes were tested, HIV-1 strains that developed resistance to 10-1074 were also resistant to PGT121 (Supplementary Table 6) . Thus, the interaction between PGT121 and additional glycans on the Env protein had little impact on the neutralizing potency of PGT121 on the naturally arising N332 or 324 G(D/N)IR 327 viral variants tested.
We also analyzed the composition of observed escape mutations in HIV-1 variants in six individuals over time. In all six individuals, the relative abundance of escape variants changed (Fig. 4) . In addition, in five of six individuals, strains carrying the intact 324 G(D/N)IR 327 protein motif and a PNGS at N332 re-emerged at 12, 16 or 24 weeks after infusion at a time when 10-1074 levels approached or were below the limit of detection (Fig. 4) . This indicates ongoing selection for both resistance and/or viral fitness after 10-1074 infusion.
Escape variants are pre-existing or rapidly generated Previous studies suggest that high viral turnover in HIV-1 infection results in a multitude of circulating mutant strains in any given individual 47, 48 . To examine the dynamics of early viral escape, we sequenced viruses present in the plasma 1 week after 10-1074 administration in seven individuals ( Supplementary Fig. 8 and Supplementary Table 5 ). We found a mixture of nonmutated and N332-PNGS-or 324 G(D/N)IR 327 -mutant viruses. Moreover, the frequency of escape variants at this early time point after infusion was inversely correlated with the duration of viral suppression (R 2 = 0.73) (Supplementary Fig. 8 ).
The kinetics of escape are consistent with pre-existing resistant viral variants in circulation at the time of infusion and/or rapid de novo generation of these mutations. To estimate the frequency of pre-existing variants and to assess how they contribute to 10-1074 escape, we performed primer-ID-based deep sequencing (PIDS) of the V3-loop region 49, 50 on plasma samples from five study participants. A total of 2,077 and 1,844 viral consensus sequences were obtained at day 0 and week 4, respectively (Supplementary Table 7 ). The obtained sampling depth was powered to detect a mutation present in 1.0% (range, 0.5-2.4%) of the viral population with 95% confidence. Whereas mutations at positions 325, 332 or 334 were found in 99.8% of the sequences in the week 4 samples, none were observed at day 0 (Supplementary Table 7 ). This indicates that the rate of potential pre-existing escape mutations is probably lower than 1.0%.
We also performed full-length envelope deep sequencing (singlemolecule real-time (SMRT) sequencing) of day 0 and week 4 samples from three of the same individuals ( Fig. 5 and Supplementary  Table 8 ) 51 . Frequencies of detected variants carrying a 325 or 332-334 mutation agreed well among SMRT sequencing, PIDS and SGS (Supplementary Table 8) . A phylogenetic tree of SMRT sequences confirmed that escape variants arose from multiple independent HIV-1 viruses (Fig. 5 and Supplementary Fig. 9 ). Out of a total of 30,711 day-0 sequences obtained by SMRT sequencing, we found D/N325K and S334R mutations in individual 1HD1 at a rate of 0.15% and 0.11%, respectively, and the S334N mutation at a rate of 0.34% in individual 1HB3. No 325 or 332-334 mutants were detected in individual 1HC2 (Fig. 5 and Supplementary Fig. 9 ). We conclude that circulating pre-existing variants carrying mutations at key positions associated with resistance to 10-1074 can be detected at very low frequency in individuals who are considered sensitive to the antibody, and that resistance originates from multiple viral variants. 34, 35 and preventing rebound viremia during analytical treatment interruption in humans 38, 52 . The two antibodies differ in their relative potency and half-lives; 3BNC117 has a somewhat longer half-life and greater potency than VRC01 (refs. 34,35,38) . As expected, these properties are reflected by the relative ability of the two antibodies to prevent infection in macaques and to prolong viral suppression in humans undergoing analytical treatment interruption 38, 52 . The finding that 10-1074 has favorable safety and pharmacokinetics profiles and is effective at decreasing viremia extends these observations to an additional nonoverlapping target of vulnerability on the HIV-1 spike.
DISCUSSION
10-1074 is more potent and has a comparable half-life to, but has a narrower spectrum of activity than, either of the two CD4-binding-site antibodies. Its effect on viremia is similar to 3BNC117, but a higher frequency of fully resistant escape variants was detected for 10-1074 than for 3BNC117 (refs. 34,37,38) . We speculate that this difference in occurrence of escape might be due to the relative cost of altering the CD4 binding site, which makes viable escape from antibodies that target this site more difficult, as has been shown in vitro 53 . As a consequence, the number of distinct escape variants that can give rise to high-level viremia might be reduced. This idea is consistent with the relative paucity of naturally arising viruses that are resistant to 3BNC117 in comparison to 10-1074 or all other glycan patch bNAbs 54 . However, we did observe that 10-1074 escape mutations are selected against in several individuals when antibody levels drop. This finding suggests that these mutations are also associated with a fitness cost in vivo.
In humanized mice and in humans, a single antibody, such as a single small-molecule drug, is insufficient to prevent the emergence of resistant viral variants because the infection produces a swarm of related mutant viruses 26, 34, 35, 55 . Similarly to what has been described for small-molecule drugs, resistance to antibodies seems to arise from pre-existing minority variants and/or de novo mutations produced during rapid HIV-1 turnover. Our findings underscore some of the similarities in antiviral activity between small-molecule drugs and antibodies and emphasize that combinations of antibodies that target nonoverlapping epitopes will be required for effective therapy and possibly prevention.
10-1074 targets an epitope that is distinct from other secondgeneration bNabs that have been tested in humans 34, 35 . It has favorable clinical characteristics and potent anti-viral activity, and therefore, 10-1074 is a promising candidate for antibody-mediated combination immunotherapy and the prevention of HIV-1 infection.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
